




# Living Cell Technologies Ltd.

ASX: LCT – OTCQX:LVCLY

## World Leading Cell Implant Company Encapsulated Porcine Cell Therapeutics

- ❖ **Diabetes** – Lead product DIABECCELL<sup>®</sup> Phase IIb trials Type 1 diabetes
- ❖ **Neurodegenerative Diseases** – NTCELL pre-clinical programs in stroke, Parkinson's, Huntington's, hearing loss
- ❖ **Cell Encapsulation** – IMMUPEL<sup>™</sup> eliminates need for immune suppression



# DIABECELL<sup>®</sup> Clinical Data Summary

## Trials

- I / IIa - Moscow, n=8; II - New Zealand, n=12, to report in 4Q10
- Other jurisdictions to be added, total patients needed for pivotal data ~ 50

## Safety

- Long term safety established; no significant adverse events; multiple implants are safe; no evidence of zoonotic (animal to human) infections; retrieved capsules showed no evidence of immune injury

## Efficacy Endpoints

- Detection of porcine insulin in blood indicating functional implant
- Normalized HbA1c – improved glycaemic control
- Reduced daily insulin dose. 2 of 7 patients off insulin
- Decreased hypoglycaemic episodes (unaware hypoglycaemia)



**DIABECELL  
Cell Implant**

# DIABECCELL® Near Term Revenue Milestones

## 2011

- Begin Final Phase (III ) pivotal trials
- Strategic alliances with leading health centers

## 2012

- Final Phase III results

## 2013

- Revenue from Russia
- LCT reaches profitability

## 2014






- Approval and revenue – NZ, Aus, US, EU, etc.
- DIABECCELL annual revenue capacity \$50 - \$60 million

## 2015

- First two manufacturing sites at capacity
- DIABECCELL annual revenue capacity ~\$80 million ~ 500 patients



# LCT's Therapeutic Pipeline

PRODUCT	DISEASE	RESEARCH	PRE-CLINICAL	CLINICAL TRIALS		
				PHASE I-IIa	PHASE II	PHASE III PIVOTAL
DIABECELL	Diabetes Type 1	 <i>NZ, Russia, others</i>				
NTCELL	Parkinsons					
NTCELL	Stroke					
NTCELL	Hearing Loss	 <i>Bionic Ear Institute, Melbourne Australia</i>				
NTCELL	Huntingtons					

# LCT Competitive Advantage

- ☑ Safety Full suite of diagnostics accredited in 45 countries  
Published long-term clinical safety data
- ☑ Approval Ethics & regulatory trial approvals, 20 patients treated
- ☑ Pig Facilities Piglet supply meets FDA standards  
Exclusive bio-certified pig herds
- ☑ Manufacturing cGMP cell processing and encapsulation
- ☑ IMMUPEL™ Immune suppression not required
- ☑ IP Broad, issued patent portfolio and knowhow

# LCT Financial Information

ASX: LCT OTCQX: LVCLY

Market Cap 15 Oct 2010: A\$45 M

Outstanding Shares: 283.8 M


ASX: 84% ,OTCQX (ADR): 16%

Total Funds Raised to Date: A\$61 M

2010 Grant Highlights:

- New Zealand Government 2010 NZ \$4 Million
- Juvenile Diabetes Research Foundation US \$0.5 Million

## Shareholdings



# LCT Value Proposition

- Consistent positive Phase II trial data
- Significant revenue potential on horizon
- Protected exclusive high-value assets
- Global, scalable product with direct channel to market
- Broad technology platform offers multiple opportunities

